Wall Street analyst estimates for Contineum Therapeutics, Inc. (CTNM): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.67 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-29 | $-0.45 | ||
| 2026-07-30 | $-0.40 | $-0.45 | +10.9% |
| 2026-05-05 | $-0.39 | $-0.55 | +29.1% |
| 2026-03-05 | $-0.49 | $-0.50 | +2.0% |
| 2025-10-30 | $-0.45 | $-0.58 | +22.4% |
| 2025-08-05 | $-0.62 | $-0.56 | -10.7% |
| 2025-05-14 | $-0.62 | $-0.56 | -10.7% |
| 2025-03-06 | $-0.56 | $-0.44 | -27.3% |
Valuation Ratios
| Price / Book | 2.04 |
| EV / EBITDA | -9.40 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | $50.0M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $258000 | 0 |
| Gross Profit | 0 | 0 | $50.0M | -$258000 | 0 |
| Research & Development | $22.4M | $16.9M | $27.6M | $38.2M | $51.5M |
| Selling, General & Admin | $6.3M | $5.8M | $6.3M | $12.5M | $16.5M |
| Operating Expenses | $28.6M | $22.7M | $66.1M | $50.6M | $68.1M |
| Operating Income | -$28.6M | -$22.7M | -$16.1M | -$50.9M | -$68.1M |
| EBITDA | -$28.3M | -$23.5M | $23.6M | -$42.0M | -$67.7M |
| Interest Expense | $332000 | $388000 | $208000 | 0 | 0 |
| Pre-tax Income | -$29.0M | -$24.3M | $23.2M | -$42.3M | -$60.0M |
| Income Tax | 0 | 0 | $450000 | 0 | 0 |
| Net Income | -$29.0M | -$24.3M | $22.7M | -$42.3M | -$60.0M |
| EPS | $-1.15 | $-0.97 | $0.13 | $-1.63 | $-2.17 |
| EPS (Diluted) | $-1.15 | $-0.97 | $0.13 | $-1.63 | $-2.17 |
| Shares Outstanding (Diluted) | $25.1M | $25.1M | $25.1M | $25.9M | $27.7M |
Price
| Price | $13.76 |
| Market Cap | $518M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACIU · ALDX · AMRN · ANRO · CADL · CAPR · KYTX
Explore sector: Healthcare · Biotechnology
More sections of CTNM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks